INTRODUCTION {#sec1-1}
============

*Lactobacillus brevis* CD2 has shown to be effective in the prevention and treatment of carious lesions and gingival--periodontal lesions.\[[@ref1][@ref2][@ref3][@ref4]\]

Shah\[[@ref4]\] demonstrated that 14 days of treatment with *L. brevis* CD2 lozenges, *L. brevis* CD2 with oral doxycycline, or doxycycline alone were all associated with statistically significant improvements in clinical measures at 2 months. Concentrations of *Aggregatibacter actinomycetemcomitans* fell sharply in all groups\[[@ref4]\] and remained very low after 2 weeks, and the probiotic groups also showed persistently increased lactobacilli concentration. *L. brevis* CD2 is thought to suppress the inflammatory process through the expression of arginine deiminase.\[[@ref3]\]

The hypothesis tested in this study was that 14 days of treatment with *L. brevis* CD2 lozenges, *L. brevis* CD2 with oral doxycycline, or doxycycline alone would have a beneficial effect on periodontal health after 5 months.

MATERIALS AND METHODS {#sec1-2}
=====================

The study design was a randomized clinical trial, approved by the Ethical Committee of Institutional Review Board. Informed written consent was obtained from all patients. Methods are described in full by Shah.\[[@ref4]\]

The study comprised 18 nonsmoking patients under the age group of 14--35 years, with sites having probing depth and clinical attachment loss ≥5 mm and bone loss to be seen radiographically. Patients were randomized to receive 14 days of treatment with *L. brevis* CD2 lozenges, *L. brevis* CD2 lozenges with oral doxycycline (100 mg tablet once daily), or doxycycline alone.\[[@ref4]\] The *L. brevis* CD2 lozenges (Inersan^®^, VSL Pharmaceuticals, Inc., Towson, MD, USA) contain 10^9^ colony-forming units per lozenge, sweetening agents such as mannitol, aspartame, and fructose, anticaking agents including talc, silicon dioxide, and magnesium stearate, and having banana flavoring.

Saliva samples were taken on day 0, after which patients underwent scaling and root planing. After 2 weeks, further saliva samples were taken, and study treatment was initiated. The third visit was at 2 months and data were reported previously.\[[@ref4]\] We now report the data for a follow-up visit at 5 months.

Clinical parameters (various parameters such as plaque index, gingival index, probing pocket depth, and clinical attachment level) were evaluated at all visits. The samples of saliva were cultured to determine the counts of lactobacilli and *A. actinomycetemcomitans*. Clinical variables were recorded as mean ± standard deviation. For both bacterial and clinical outcome measures, one-way analysis of variance (ANOVA) was used to compare data from the different groups at each time interval. Changes between groups were evaluated using repeated measure ANOVA.

RESULTS {#sec1-3}
=======

Clinical parameters at 5 months are shown in [Table 1](#T1){ref-type="table"}.

###### 

Clinical parameters at baseline and 5 months

![](JISP-21-341-g001)

All clinical parameters are shown to be numerically improved at 5 months when compared with baseline in all three groups. The improvement (*P* \< 0.01) in gingival index was statistically significant, and the intergroup results were also statistically significant (*P* \< 0.01). The improvements in plaque amount, probing depth, and clinical attachment level did not reach statistical significance and found no significant difference between groups.

There found to be statistically significant difference between mean lactobacilli counts for the three groups at 5 months (*P* = 0.04). Counts peaked at 2 months in the probiotic groups. The *L. brevis* CD2 alone group showed the highest peak counts, and counts in this group remained above baseline at 5 months \[[Figure 1](#F1){ref-type="fig"}\]. Lactobacilli counts in the *L. brevis* CD2 plus doxycycline group peaked at just under 60% of the levels seen with *L. brevis* CD2 alone and had returned to baseline at 5 months. Lactobacilli counts were close to 0 at 5 months in the doxycycline alone group. Counts of *A. actinomycetemcomitans* were minimal from 2 weeks in all groups and were unchanged between the 2- and 5-month visits (data not shown).

![Lactobacilli concentration (colony-forming unit/ml). One-way ANOVA was used to compare data in the different groups at each time interval. Changes between groups were evaluated using repeated measure ANOVA](JISP-21-341-g002){#F1}

DISCUSSION {#sec1-4}
==========

These data confirm that 14 days of treatment with *L. brevis* CD2 lozenges have a lasting effect on clinical measures of periodontitis, particularly gingival index. This effect appears to be equivalent to that produced by doxycycline. No synergy was observed when the two agents were administered concomitantly. Concentrations of lactobacilli remained elevated 5 months after treatment with *L. brevis* CD2 alone, but not when *L. brevis* CD2 was administered with doxycycline. Comparing probiotics with antibiotics, probiotics could be used as an alternative to antibiotics in the treatment of patients with aggressive periodontitis, without the risks of promoting antibiotic resistance and/or disturbing the body microflora.
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